Skip to main content
ESPR
NASDAQ Life Sciences

艾斯佩里昂治疗公司预计2026年运营费用在2.25亿美元至2.55亿美元之间

feedReported by Dow Jones Newswires
Sentiment info
Neutral
Importance info
7
Price
$3.15
Mkt Cap
$726.753M
52W Low
$0.693
52W High
$4.175
Market data snapshot near publication time

summarizeSummary

艾斯佩里昂治疗公司已经提供了2026年的运营费用指导，预计费用将在2.25亿美元至2.55亿美元之间。这一前瞻性财务信息对于投资者更新其财务模型和评估公司未来的盈利能力和现金流烧损至关重要。虽然时间表显示最近收购了Corstasis Therapeutics，但这一费用指导是新的信息，将被纳入公司的整体财务前景中。交易者将会根据分析师的共识和潜在的影响来评估这一指导对公司实现盈利的路径，尤其是在最近的并购活动的背景下。

在该公告发布时，ESPR的交易价格为$3.15，交易所为NASDAQ，所属行业为Life Sciences，市值约为$7.3亿。 52周交易区间为$0.69至$4.18。 这则新闻被评估为中性市场情绪，重要性评分为7/10。 来源：Dow Jones Newswires。

show_chartPrice Chart

Share this article

Copied!

feed ESPR - Latest Insights

ESPR
Apr 16, 2026, 4:11 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Esperion Seeks Shareholder Approval for 7M Share Equity Plan Increase and Announces Board Changes
Sentiment: Neutral
View Wiseek Article
ESPR
Apr 02, 2026, 4:22 PM EDT
Filing Type: 8-K
Importance Score:
9
Esperion Completes Corstasis Acquisition, Adds FDA-Approved Enbumyst to Cardiovascular Portfolio
Sentiment: Positive
View Wiseek Article
ESPR
Apr 02, 2026, 4:00 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Esperion Closes Corstasis Acquisition, Bolstering Cardiovascular Franchise with Enbumyst™
Sentiment: Positive
View Wiseek Article
ESPR
Mar 16, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
Esperion's Bempedoic Acid Secures Multiple Class 1 Recommendations in Major Dyslipidemia Guidelines
Sentiment: Positive
View Wiseek Article
ESPR
Mar 10, 2026, 4:55 PM EDT
Filing Type: 10-K
Importance Score:
9
Esperion Therapeutics Reports Strong 2025 Revenue Growth, Reduced Loss, Confirms Corstasis Acquisition, But Faces Material Weakness in Internal Controls
Sentiment: Neutral
View Wiseek Article
ESPR
Mar 10, 2026, 7:17 AM EDT
Filing Type: 8-K
Importance Score:
9
Esperion Reports Strong Q4 Revenue & Profit, Secures Key Patent Exclusivity to 2040
Sentiment: Positive
View Wiseek Article
ESPR
Mar 10, 2026, 6:02 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Esperion Therapeutics Projects 2026 Operating Expenses Between $225M and $255M
Sentiment: Neutral
View Wiseek Article
ESPR
Mar 03, 2026, 7:03 AM EST
Filing Type: 8-K
Importance Score:
9
Esperion to Acquire Corstasis Therapeutics for $75M Upfront, Expanding Cardiovascular Franchise with FDA-Approved Enbumyst
Sentiment: Positive
View Wiseek Article
ESPR
Mar 03, 2026, 6:00 AM EST
Source: Dow Jones Newswires
Importance Score:
8
Esperion to Acquire Corstasis, Expanding Cardiovascular Franchise with Enbumyst(TM)
Sentiment: Positive
View Wiseek Article
ESPR
Jan 12, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
9
Esperion Secures Key Patent Settlements Extending Exclusivity to 2040, Reports Strong 2025 Sales Growth, and Unveils Vision 2040
Sentiment: Positive
View Wiseek Article